TxCell develops cellular immunotherapy platforms based on antigen-specific regulatory T cells. The Company's products are used for the treatment of severe autoimmune and inflammatory diseases, as well as transplantation-related inflammatory disorders.

TypeSubsidiary
HQValbonne, FR
Founded2001
Websitetxcell.com
Cybersecurity ratingBMore
TxCell was founded in 2001 and is headquartered in Valbonne, FR

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at TxCell

Stephane Boissel

Stephane Boissel

CEO
Raphael Flipo

Raphael Flipo

SVP, Chief Financial Officer
Francois Meyer

Francois Meyer

Chairman of the Board and Head of Research
Show more

TxCell Office Locations

TxCell has an office in Valbonne
Valbonne, FR (HQ)
Allée de la Nertière
Show all (1)

TxCell Financials and Metrics

Summary Metrics

Founding Date

2001

Total Funding

$71.6 m

Investors

TxCell Revenue

TxCell's revenue was reported to be €2.23 m in FY, 2017 which is a 24.2% decrease from the previous period.
Annual
EURFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

3.4m4.6m2.9m2.2m

Revenue growth, %

36%(36%)(24%)

General and administrative expense

2.2m3.5m4.5m3.2m

R&D expense

7.8m10.8m10.5m8.5m
Half Year
EURH1, 2015H1, 2016H1, 2017H1, 2018

Revenue

2.0m1.4m1.3m1.0m

General and administrative expense

1.9m2.5m1.8m1.9m

R&D expense

5.7m5.6m3.9m4.7m

Operating expense total

7.6m8.1m5.7m6.8m
Annual
EURFY, 2014FY, 2015FY, 2016FY, 2017

Cash

13.9m9.2m3.5m4.9m

Accounts Receivable

1.0m4.0k4.0k

Current Assets

18.5m13.8m5.8m7.5m

PP&E

1.4m876.0k736.0k625.0k
Half Year
EURH1, 2015H1, 2016H1, 2017

Cash

7.7m3.2m8.7m

Accounts Receivable

233.0k4.0k7.0k

Current Assets

13.3m7.3m11.3m

PP&E

1.3m836.0k631.0k
Annual
EURFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(8.3m)(11.3m)(13.6m)(10.9m)

Depreciation and Amortization

460.0k1.1m(326.0k)272.0k

Accounts Payable

5.8m213.0k(714.0k)(19.0k)

Cash From Operating Activities

(6.9m)(10.1m)(10.4m)(9.8m)
Half Year
EURH1, 2015H1, 2016H1, 2017

Net Income

(5.7m)(7.1m)(5.3m)

Depreciation and Amortization

257.0k(445.0k)107.0k

Accounts Payable

(146.0k)503.0k219.0k

Cash From Operating Activities

(6.3m)(6.1m)(5.1m)
EURFY, 2014

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.4 x
Show all financial metrics

TxCell Operating Metrics

FY, 2015FY, 2016FY, 2017

Patents Licensed

125 200 170
Show all operating metrics

TxCell Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

TxCell Online and Social Media Presence

Embed Graph

TxCell News and Updates

Sangamo Therapeutics to Acquire TxCell

RICHMOND, Calif. and VALBONNE, France, July 23, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) and TxCell S.A. (ENXTPA: TXCL) announced today that they have entered into a definitive agreement on July 20, 2018 pursuant to which Sangamo will, following the completion of the ...

TxCell Blogs

Sangamo Therapeutics Announces Third Quarter 2020 Conference Call and Webcast

BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 28, 2020-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2020 financial results after the market closes on Wednesday, November 4, 2020 .

Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy

Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy ronryan.teano@… Thu, 06/18/2020 - 09:01 Pfizer and Sangamo Announce Up…

Sangamo Therapeutics Announces Participation at the Jefferies Virtual Healthcare Conference

BRISBANE, Calif. --(BUSINESS WIRE)--May 29, 2020-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 4:00 p.m. ET . The presentation will be webcast live and may be

Sangamo Announces Preliminary Results From the First Three Patients in a Phase 1/2 Study Evaluating ST-400 Ex Vivo Gene-edited Cell Therapy in Beta Thalassemia

First three patients experienced prompt hematopoietic reconstitution, and no clonal hematopoiesis Early first-in-human data provide insights into relationship between product specific characteristics, including cell dose, editing efficiency, and fetal hemoglobin induction Additional study results

Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment

Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment Content Import Sat, 12/07/2019 - 09:00 Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VI…

Sangamo Therapeutics Announces Nature Medicine Publication Detailing the Activity of Disease Allele-Selective Zinc Finger Proteins in Preclinical Models of Huntington’s Disease

Sangamo Therapeutics Announces Nature Medicine Publication Detailing the Activity of Disease Allele-Selective Zinc Finger Proteins in Preclinical Models of Huntington’s Disease Content Import Mon, 07/01/2019 - 11:00 Sangamo Therapeutics Announces Nature Medicine Publication Detailing the A…
Show more

TxCell Frequently Asked Questions

  • When was TxCell founded?

    TxCell was founded in 2001.

  • Who are TxCell key executives?

    TxCell's key executives are Stephane Boissel, Raphael Flipo and Francois Meyer.

  • How many employees does TxCell have?

    TxCell has 21 employees.

  • What is TxCell revenue?

    Latest TxCell annual revenue is €2.2 m.

  • What is TxCell revenue per employee?

    Latest TxCell revenue per employee is €106.4 k.

  • Who are TxCell competitors?

    Competitors of TxCell include Bioz, Karius and eGenesis.

  • Where is TxCell headquarters?

    TxCell headquarters is located at Allée de la Nertière, Valbonne.

  • Where are TxCell offices?

    TxCell has an office in Valbonne.

  • How many offices does TxCell have?

    TxCell has 1 office.